CTRI/2020/05/025224.

Study name	Study to efficacy of Ivermectin in patients of COVID‐19
Methods	Trial design: open‐label RCT with 2 parallel arms Type of record: trial register entry Sample size: 50 Setting: inpatient Country: India Language: English Number of centres: 1 Study purpose (treatment, prevention): treatment Trial registration number: CTRI/2020/05/025224 Date of registration: 18 May 2020
Participants	Inclusion criteria Adults (age 18–75 years) Laboratory‐confirmed SARS‐CoV‐2 infection In the view of the responsible doctor, no contraindication to any of the study treatments  Hospitalized at R D Gardi Medical College, Ujjain Madhya Pradesh Exclusion criteria Anticipated transfer to another hospital, within 72 hours, which is not a study site Known allergy to study medication or its components (non‐medicinal ingredients) Known HIV infection
Interventions	Details of intervention Type and dose: ivermectin 12 mg, once daily for 2 days Route of administration: oral Treatment details of control group No treatment except standard of care Concomitant therapy: standard of care according to hospital guidelines administered in both study arms
Outcomes	Primary study outcome Eradication of virus at 1, 3, and 5 days Relevant review outcomes planned Duration of hospitalisation Additional study outcomes Overall safety of study drug Improvement in the abnormal laboratory values
Starting date	24 May 2020
Contact information	Dr Ashish Pathak  R. D. Gardi Medical College Department of Pediatrics  Agar Road, Surasa Ujjain  MADHYA PRADESH  456006  India drashish.jpathak@gmail.com
Notes	Recruitment status: not yet recruiting Prospective completion date: NR Date last update posted: 18 May 2020 Sponsor/funding: R. D. Gardi Medical College